FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890413633> ?p ?o ?g. }

• W2890413633 endingPage "7516" @default.
• W2890413633 startingPage "7516" @default.
• W2890413633 abstract "7516 Background: In the relapsed/refractory (R/R) setting for indolent non-Hodgkin lymphoma (iNHL), duration of response (DOR) to and types of prior therapy are important factors in predicting outcomes to subsequent therapy. Lenalidomide plus rituximab (R2) has shown promising efficacy and tolerability in multiple NHL studies. This report explores the association between prior number of therapies and response to R2. Methods: MAGNIFY (NCT01996865) is a phase IIIb, multicenter, global study of R/R NHL patients, including follicular lymphoma (FL) grade 1-3a and marginal zone lymphoma (MZL). Patients receive 12 cycles of R2 (lenalidomide 20 mg/d, d1-21/28 + standard rituximab). Patients with stable disease or better are then randomized 1:1 to maintenance with R2 vs rituximab alone. This analysis focuses on the initial period before randomization (12 cycles R2) for patients with <2 (<2L) vs ≥2 lines (≥2L) of prior systemic anti-lymphoma therapies. Results: As of May 1, 2017, 232 patients with FL gr1-3a (n = 186) and MZL (n = 46) were enrolled for the initial treatment period. Overall, median age was 66 years (range 35-91) and 89% were stage III/IV. Patients received a median of 2 prior systemic treatments (31% ≥3) and 97% received prior rituximab-containing regimens. Analyzed subgroups included 43% <2L (n = 99) and 57% ≥2L (n = 133) with generally similar baseline characteristics. In efficacy-evaluable patients, the overall response rates (70% and 66%) and complete response (51% and 36%) were similar in <2L and ≥2L patients. Median time to response was 2.8 months (range, 2-12) for both groups. For <2L and ≥2L groups, 1-year rates for PFS were 68% and 70%, and DOR were 77% and 81%, respectively. The most common grade ≥3 treatment-emergent adverse events for <2L and ≥2L patients, respectively, were neutropenia (29%; 37%), thrombocytopenia (10%; 6%), and leukopenia (4%; 7%). Conclusions: R2 therapy showed favorable activity and tolerable safety profiles in patients who had R/R FL and MZL, regardless of the number of prior anti-lymphoma therapies. Enrollment in MAGNIFY is ongoing. Clinical trial information: NCT01996865." @default.
• W2890413633 created "2018-09-27" @default.
• W2890413633 creator A5001204133 @default.
• W2890413633 creator A5009060912 @default.
• W2890413633 creator A5013007045 @default.
• W2890413633 creator A5035594574 @default.
• W2890413633 creator A5038099073 @default.
• W2890413633 creator A5041491201 @default.
• W2890413633 creator A5045105562 @default.
• W2890413633 creator A5049845550 @default.
• W2890413633 creator A5072266160 @default.
• W2890413633 creator A5078844706 @default.
• W2890413633 creator A5081795255 @default.
• W2890413633 creator A5082720713 @default.
• W2890413633 creator A5084853102 @default.
• W2890413633 creator A5091692538 @default.
• W2890413633 date "2018-05-20" @default.
• W2890413633 modified "2023-09-27" @default.
• W2890413633 title "Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL." @default.
• W2890413633 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.7516" @default.
• W2890413633 hasPublicationYear "2018" @default.
• W2890413633 type Work @default.
• W2890413633 sameAs 2890413633 @default.
• W2890413633 citedByCount "6" @default.
• W2890413633 countsByYear W28904136332018 @default.
• W2890413633 countsByYear W28904136332019 @default.
• W2890413633 countsByYear W28904136332020 @default.
• W2890413633 countsByYear W28904136332021 @default.
• W2890413633 crossrefType "journal-article" @default.
• W2890413633 hasAuthorship W2890413633A5001204133 @default.
• W2890413633 hasAuthorship W2890413633A5009060912 @default.
• W2890413633 hasAuthorship W2890413633A5013007045 @default.
• W2890413633 hasAuthorship W2890413633A5035594574 @default.
• W2890413633 hasAuthorship W2890413633A5038099073 @default.
• W2890413633 hasAuthorship W2890413633A5041491201 @default.
• W2890413633 hasAuthorship W2890413633A5045105562 @default.
• W2890413633 hasAuthorship W2890413633A5049845550 @default.
• W2890413633 hasAuthorship W2890413633A5072266160 @default.
• W2890413633 hasAuthorship W2890413633A5078844706 @default.
• W2890413633 hasAuthorship W2890413633A5081795255 @default.
• W2890413633 hasAuthorship W2890413633A5082720713 @default.
• W2890413633 hasAuthorship W2890413633A5084853102 @default.
• W2890413633 hasAuthorship W2890413633A5091692538 @default.
• W2890413633 hasConcept C121332964 @default.
• W2890413633 hasConcept C126322002 @default.
• W2890413633 hasConcept C141071460 @default.
• W2890413633 hasConcept C142424586 @default.
• W2890413633 hasConcept C143998085 @default.
• W2890413633 hasConcept C197934379 @default.
• W2890413633 hasConcept C204243189 @default.
• W2890413633 hasConcept C2776063141 @default.
• W2890413633 hasConcept C2776364478 @default.
• W2890413633 hasConcept C2777058707 @default.
• W2890413633 hasConcept C2778375690 @default.
• W2890413633 hasConcept C2779338263 @default.
• W2890413633 hasConcept C2780653079 @default.
• W2890413633 hasConcept C31760486 @default.
• W2890413633 hasConcept C535046627 @default.
• W2890413633 hasConcept C61943457 @default.
• W2890413633 hasConcept C71924100 @default.
• W2890413633 hasConcept C87355193 @default.
• W2890413633 hasConcept C90924648 @default.
• W2890413633 hasConceptScore W2890413633C121332964 @default.
• W2890413633 hasConceptScore W2890413633C126322002 @default.
• W2890413633 hasConceptScore W2890413633C141071460 @default.
• W2890413633 hasConceptScore W2890413633C142424586 @default.
• W2890413633 hasConceptScore W2890413633C143998085 @default.
• W2890413633 hasConceptScore W2890413633C197934379 @default.
• W2890413633 hasConceptScore W2890413633C204243189 @default.
• W2890413633 hasConceptScore W2890413633C2776063141 @default.
• W2890413633 hasConceptScore W2890413633C2776364478 @default.
• W2890413633 hasConceptScore W2890413633C2777058707 @default.
• W2890413633 hasConceptScore W2890413633C2778375690 @default.
• W2890413633 hasConceptScore W2890413633C2779338263 @default.
• W2890413633 hasConceptScore W2890413633C2780653079 @default.
• W2890413633 hasConceptScore W2890413633C31760486 @default.
• W2890413633 hasConceptScore W2890413633C535046627 @default.
• W2890413633 hasConceptScore W2890413633C61943457 @default.
• W2890413633 hasConceptScore W2890413633C71924100 @default.
• W2890413633 hasConceptScore W2890413633C87355193 @default.
• W2890413633 hasConceptScore W2890413633C90924648 @default.
• W2890413633 hasIssue "15_suppl" @default.
• W2890413633 hasLocation W28904136331 @default.
• W2890413633 hasOpenAccess W2890413633 @default.
• W2890413633 hasPrimaryLocation W28904136331 @default.
• W2890413633 hasRelatedWork W2727802946 @default.
• W2890413633 hasRelatedWork W2926744043 @default.
• W2890413633 hasRelatedWork W2951347740 @default.
• W2890413633 hasRelatedWork W3168899802 @default.
• W2890413633 hasRelatedWork W3175867787 @default.
• W2890413633 hasRelatedWork W3216465163 @default.
• W2890413633 hasRelatedWork W4281678979 @default.
• W2890413633 hasRelatedWork W4283328755 @default.
• W2890413633 hasRelatedWork W4296532704 @default.
• W2890413633 hasRelatedWork W4296533012 @default.
• W2890413633 hasVolume "36" @default.
• W2890413633 isParatext "false" @default.
• W2890413633 isRetracted "false" @default.

• next